重组人生长激素治疗肝硬化低清蛋白血症

目的:观察重组人生长激素(rhGH)治疗肝硬化引起的低清(白)蛋白血症的临床疗效。方法:选择血清清蛋白低于30g·L-1的肝硬化病人46例,男性39例,女性7例,分为治疗组、对照组各23例。治疗组在常规保肝及对症治疗基础上,给予rhGH,4IU,皮下注射,每日1次,连续14d;对照组仅给予常规保肝及对症治疗,14d为一个疗程。检测2组病人治疗前及治疗结束d1和4wk后血清清蛋白及其他肝功能指标变化,并进行临床观察。结果:治疗组治疗前血清清蛋白(25±s3)g·L-1,治疗结束d1血清清蛋白(31±3)g·L-1(P<0.01),4wk后血清清蛋白(33±3)g·L-1(P<0.01);对照组治疗前血清清蛋白(25±3)g·L-1,治疗结束d1血清清蛋白(25±3)g·L-1,4wk后血清清蛋白(24.4±2.6)g·L-1(P>0.05),2组治疗结束d1及4wk后血清清蛋白相比,差异有非常显著意义(P<0.01)。治疗结束d1及4wk内治疗组比对照组病人精神状态、食欲、尿量、腹腔积液、肝功能等均明显改善且持续稳定,有显著差异(P<0.05)。无明显不良反应。结论:rhGH可以增加肝硬化病人的血清清蛋白的水平,改善营养状况,无明显不良反应。

Clinical efficacy of recombinant human growth hormone in treatment of liver cirrhosis with hypoproteinemia

AIM:To evaluate the clinical efficacy of recombined human somatotropin (rhGH) in treatment of liver cirrhosis with hypoproteinemia. METHODS:Forty-six patients with hypoalbumia caused by liver cirrhosis were enrolled into this study (M 39, (F 7)). All patients were divided into two groups (with 23 patients in each for the experimental group and control group). Patients in experimental group received rhGH, 4 IU·d~(-1), sc, along with traditional therapy, while control group received traditional therapy only; the whole course covered 14 d. For each group serum albumin levels and other hepatic functions were measured before, the d 1 and 4 wk after the treatment, (respectively.) RESULTS:Serum albumin levels in experimental group showed significant differences between before treatment and d 1,4 wk after the treatment ((25±s 3) vs (31±3) vs (33±3) g·L~(-1), (P<0.01)), while control group showed no significant differences ((25±3) vs (25±3)vs (24.4±2.6) (g·)L~(-1), P>0.05). There were also remarkable differences between the two groups on the d 1 and 4 wk after the treatment (P<0.01). General condition of the experimental group including apetide, urine excretion volume ascites ,liver function was obviously promoted and persisting stable than those of the controls(P<(0.05)). No adverse reactions occured in experimental group. CONCLUSION:rhGH is effective,promising and less complication in the treatment of liver cirrhosis with hypoalbumia.